Drugs / Co-Latanoprost
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02792803 | Sep 2015 → Apr 2017 | ocular hypertension, open-angle glaucoma | Dr. David Yan | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Co-Latanoprost | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02792803 ↗ |
| Modality | Other / unclassified | “A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.” NCT02792803 ↗ |
| Route | Other | “Patients will take one drop of the assigned drops in the affected eye every evening at 2100 hrs (+- 1 hr)” NCT02792803 ↗ |